French Sanofi and German BioNTech AG have partnered up to develop up to five immunotherapies for the treatment of cancer. BioNTechâ€™s mRNA technology platform is the basis of the deal.
According to the exclusive collaboration and license agreement, Sanofi will pay BioNTech US$60m (â‚¬54m) upfront and up to US$300m (â‚¬273m) later in milestone payments. The Mainz-based mRNA specialist will also be eligible to royalty payments for any production commercialised. In addition, BioNTech retains the option to co-develop and co-commercialise two of the five products with Sanofi in the EU and the US.
The collaboration will utilise BioNTechâ€™s mRNA formulation technology, which enables targeted mRNA delivery in vivo, to generate novel cancer immunotherapies. BioNTech will also supply part of the mRNA material needed for development activities from its in-house GMP manufacturing unit.